Cargando…

First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer

OBJECTIVES: Food and Drug Administration (FDA) approved crizotinib for advanced ROS1‐rearranged (ROS1+) non‐small‐cell lung cancer (NSCLC) patients due to a single‐arm study PROFILE 1001. However, there is no direct comparison between crizotinib and platinum‐pemetrexed chemotherapy. MATERIALS AND ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Lan, Qiang, Tan, Li, Ziming, Ding, Ding, Yu, Yongfeng, Lu, Shun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221427/ https://www.ncbi.nlm.nih.gov/pubmed/32167664 http://dx.doi.org/10.1002/cam4.2972

Ejemplares similares

Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement
por: Zhang, Limin, et al.
Publicado: (2016)

Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different ROS1 fusion variants
por: Xu, Haiyan, et al.
Publicado: (2020)

Patients with ROS1 rearrangement‐positive non‐small‐cell lung cancer benefit from pemetrexed‐based chemotherapy
por: Song, Zhengbo, et al.
Publicado: (2016)

Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients
por: Cui, Shaohua, et al.
Publicado: (2016)

Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2019)

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
por: Krawczyk, Paweł, et al.
Publicado: (2014)

Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
por: Zhai, Xiaoyu, et al.
Publicado: (2017)

Crizotinib versus platinum‐based double‐agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase‐positive lung adenocarcinoma
por: Zhang, Quan, et al.
Publicado: (2015)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
por: Takeyasu, Yuki, et al.
Publicado: (2022)

Crizotinib, an Effective Agent in ROS1-Rearranged Adenocarcinoma of Lungs: A Case Report
por: Joshua, Julie Mariam, et al.
Publicado: (2018)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
por: Mansfield, A. S., et al.
Publicado: (2022)

Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
por: Eisner, Joel R., et al.
Publicado: (2023)

Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
por: Lu, Shun, et al.
Publicado: (2016)

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada
por: Beca, Jaclyn M., et al.
Publicado: (2021)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Miyamoto, Yosuke, et al.
Publicado: (2021)

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
por: Suryavanshi, Moushumi, et al.
Publicado: (2017)

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
por: Sehgal, Kartik, et al.
Publicado: (2020)

A case of ROS1‐rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib
por: Tachi, Hiroaki, et al.
Publicado: (2020)

Peripheral Lung Squamous Carcinoma With ROS1 Rearrangement Sensitive to Crizotinib: A Case Report
por: Yang, Guangdie, et al.
Publicado: (2021)

Successful Treatment with Low-dose Crizotinib in a Patient with ROS1-rearranged Lung Cancer Who Developed Crizotinib-induced Heart Failure
por: Hashimoto, Takahiko, et al.
Publicado: (2022)

Prognostic value of early radiological response to first‐line platinum‐containing chemotherapy in patients with metastatic nasopharyngeal carcinoma
por: Liu, Guo‐Ying, et al.
Publicado: (2019)

Complex renal cysts associated with crizotinib treatment
por: Schnell, Patrick, et al.
Publicado: (2015)

Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer
por: Shi, Yafei, et al.
Publicado: (2023)

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
por: Ryu, Woo Kyung, et al.
Publicado: (2022)

Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer
por: Song, Peng, et al.
Publicado: (2019)

Successful Treatment of ROS1-rearranged Lung Cancer Complicated by Hypertrophic Pulmonary Osteoarthropathy with Crizotinib Therapy
por: Katsurada, Naoko, et al.
Publicado: (2019)

Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
por: Zhang, Yongchang, et al.
Publicado: (2022)

Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients
por: Zhang, Huixian, et al.
Publicado: (2023)

Crizotinib targets in glioblastoma stem cells
por: Junca, Audelaure, et al.
Publicado: (2017)

Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China
por: Lu, Shun, et al.
Publicado: (2018)

Small cell transformation in crizotinib‐resistant ROS1‐rearranged non‐small cell lung cancer with retention of ROS1 fusion: A case report
por: Wu, Chi‐Hao, et al.
Publicado: (2021)

Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report
por: Begum, Parvin, et al.
Publicado: (2022)

Single pemetrexed is noninferior to platinum-based pemetrexed doublet as first-line treatment on elderly Chinese patients with advanced nonsquamous nonsmall cell lung cancer
por: Pu, Xiaolin, et al.
Publicado: (2017)

Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis
por: Paik, Seung Sook, et al.
Publicado: (2018)

Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China
por: Liu, Huiqin, et al.
Publicado: (2022)

Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort
por: Gibson, Amanda J. W., et al.
Publicado: (2022)

Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study
por: Zhang, Yongchang, et al.
Publicado: (2021)

Prediction of response and adverse drug reaction of pemetrexed plus platinum-based chemotherapy in lung adenocarcinoma by serum metabolomic profiling
por: Gong, Wei-Jing, et al.
Publicado: (2022)

Correction: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China
por: Liu, Huiqin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t9kig1bb461asd3h367tlmlgqd